Hain on organic developments
This article was originally published in The Rose Sheet
Executive Summary
Hain Celestial says it supports the National Organic Standards Board's recommendation (by 12 to 1 vote) for the U.S. Department of Agriculture to police the organic personal-care sector as it does the food industry, with respect to standards established under the National Organic Program. In a Nov. 12 release, Hain states: "A few natural product competitors and their supporters have attempted to misrepresent the NOSB recommendation in an unfortunate effort to unfairly disparage our brands." The Organic Consumers Association celebrated NOSB's Nov. 5 recommendation as a victory against brands perpetrating "organic cosmetics fraud," the same brands targeted by the group's recently launched boycott, which includes Hain's Jason and Avalon Organics lines. "Hain Celestial will continue to work with industry participants and government agencies to draft and formalize standards surrounding the use of the term 'organic' in personal-care products. Until such standards are established, it is up to all of us in the industry to work together to self-regulate for label integrity and consumer clarity," says Hain, a founding member of the OASIS coalition (1"The Rose Sheet" Aug. 10, 2009)
You may also be interested in...
OASIS Upholds Value Of Private Organic Standards, Points To Food History
The Organic And Sustainable Industry Standards association maintains that litigation and quibbling over certification criteria are counterproductive, in that ultimately it is the consumer who loses out
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.